By Andrés Ricaurte Fajardo, MD,1 Joseph Osborne, MD, PhD,1 Lady Sawoszczyk, BS, CNMT2
Data and images courtesy of New York-Presbyterian Hospital/Weill Cornell Medical Center, New York, New York, USA
Fast, quantitative SPECT/CT acquisition following multiple therapy cycles of 177Lu-PSMA-617 enables response assessment in a patient with metastatic prostate cancer
2023-03-13
A male in his 70s with a history of prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) underwent routine 68Ga-PSMA-11 PET/CT imaging on Biograph mCT Flow™ PET/CT. 68Ga-PSMA-11 PET/CT findings confirmed PSMA expression in the metastatic disease, which qualified the patient for 177Lu-PSMA-617 treatment. The patient received 177Lu-PSMA-617 therapy followed by fast, multi-bed, quantitative SPECT/CT imaging after each treatment cycle. This clinical case demonstrates how Symbia Intevo Bold™ with xSPECT Quant™ enables 177Lu-PSMA-617 treatment response assessment.
Clinical case study